Fulltext

Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting

Kim CS 1 , Lee JY 2 , Chung BH 3 , Kim WJ 4 , Fai NC 5 , Hakim L 6 Show all authors , Umbas R 7 , Ong TA 8 , Lim J 8 , Letran JL 9 , Chiong E 10 , Wu TL 11 , Lojanapiwat B 12 , Türkeri L 13 , Murphy DG 14 , Gardiner RA 15 , Moretti K 16 , Cooperberg M 17 , Carroll P 18 , Mun SK 19 , Hinotsu S 20 , Hirao Y 21 , Ozono S 22 , Horie S 23 , Onozawa M 24 , Kitagawa Y 25 , Kitamura T 26 , Namiki M 27 , Akaza H 28

Affiliations 

  • 1 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
  • 2 Department of Urology, St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
  • 3 Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
  • 4 Department of Urology, Chungbuk National Medical University Hospital, Cheongju, South Korea
  • 5 SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
  • 6 Department of Urology, Airlangga University/Dr. Soetomo General Hospital of Surabaya, Surabaya, East Java, Indonesia
  • 7 Department of Urology, Dr. Cipto Mangunkusumo Hospital/Faculty of Medicine, University of Indonesia, Depok City, West Java, Indonesia
  • 8 Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 9 Department of Urology, Cardinal Santos Medical Center, Manila, Philippines
  • 10 Department of Urology, University Surgical Cluster, National University Health System (NUHS), Singapore
  • 11 Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
  • 12 Department of Surgery, Faculty of Medicine, Chiang Mai University, Thailand
  • 13 Department of Urology, Acıbadem University Medical Faculty, Istanbul, Turkey
  • 14 Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  • 15 University of Queensland Centre for Clinical Research at Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia
  • 16 School of Population Health, University of South Australia, Adelaide, SA, Australia
  • 17 Department of Urology, School of Medicine, University of California San Francisco, San Francisco, CA, USA
  • 18 Department of Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
  • 19 Open Source Electronic Health Record Alliance, Arlington, VA, USA
  • 20 Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan
  • 21 Osaka Gyoumeikan Hospital, Osaka, Japan
  • 22 Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • 23 Department of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan
  • 24 Department of Urology, Tokyo Kita Medical Center, Tokyo, Japan
  • 25 Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
  • 26 Faculty of Medicine, University of Tokyo, Tokyo, Japan
  • 27 Graduate School of Medical Science, Kanazawa University, Japan
  • 28 Department of Strategic Investigation on Comprehensive Cancer Network, Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo, Japan
Prostate Int, 2017 Sep;5(3):95-103.
PMID: 28828352 DOI: 10.1016/j.prnil.2017.03.006

Abstract

The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The study was launched in December 2015 in Tokyo, Japan, and the participating countries and regions engaged in preparations for the study during the course of 2016, including patient registration and creation of databases for the purpose of the study. The Second A-CaP Meeting was held on September 8, 2016 in Seoul, Korea, with the participation of members and collaborators from 12 countries and regions. Under the study, each participating country or region will begin registration of newly diagnosed prostate cancer patients and conduct prognostic investigations. From the data gathered, common research themes will be identified, such as comparisons among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the first Asia-wide study of prostate cancer and has developed from single country research efforts in this field, including in Japan and Korea. At the Second Meeting, participating countries and regions discussed the status of preparations and discussed various issues that are being faced. These issues include technical challenges in creating databases, promoting participation in each country or region, clarifying issues relating to data input, addressing institutional issues such as institutional review board requirements, and the need for dedicated data managers. The meeting was positioned as an opportunity to share information and address outstanding issues prior to the initiation of the study. In addition to A-CaP-specific discussions, a series of special lectures was also delivered as a means of providing international perspectives on the latest developments in prostate cancer and the use of databases and registration studies around the world.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications